Safety and immunogenicity of a live attenuated varicella vaccine in VZV-seropositive HIV-infected adults.

BACKGROUND Herpes-zoster is common in HIV-infected patients in spite of antiretroviral therapy. We evaluated the safety and immunogenicity of a live attenuated varicella-zoster virus (VZV) vaccine as a candidate for protecting HIV-infected adults against herpes-zoster. RESULTS Sixty-seven HIV-infected and 15 uninfected subjects, 18 to 65 years old, were… CONTINUE READING